TY - GEN
T1 - 3% Hypertonic saline following subarachnoid hemorrhage in rats
AU - Lee, Steve
AU - Stier, Gary
AU - Marcantonio, Suzzanne
AU - Lekic, Tim
AU - Allard, Martin
AU - Martin, Robert
AU - Zhang, John
N1 - Part of the Acta Neurochirurgica Supplementum book series (NEUROCHIRURGICA, volume 102) Background Hypertonic saline (HTS) has been proposed as a treatment after aneurysmal subarachnoid hemorrhage (SAH) to minimize ischemic brain injury due to its osmotic and rheologic properties. Although the benefits of 7.2% HTS use in brain injury have been studied, there is a paucity of data on the use of 3%HTS.
PY - 2009/1/9
Y1 - 2009/1/9
N2 - Background Hypertonic saline (HTS) has been proposed as a treatment after aneurysmal subarachnoid hemorrhage (SAH) to minimize ischemic brain injury due to its osmotic and rheologic properties. Although the benefits of 7.2% HTS use in brain injury have been studied, there is a paucity of data on the use of 3%HTS. Methods We investigated whether 3%HTS can reduce brain water content and improve neurologic function after SAH in the rodent model compared to 0.9% saline solution (NS). Neurologic testing was conducted at 24 hours post-SAH prior to sacrificing animals for brain water content evaluation. Findings There was significant potentiation of brain water content in the right hemisphere between 3%HTS and NS groups. The modified Garcia score was not significantly different between the two groups; however, the vibrissae-stimulated forelimb placement test showed significantly lower scores in the HTS group. 3%HTS does not decrease brain edema or improve neurologic deficits as compared to NS. In fact, our study showed 3%HTS potentiated brain edema and worsened neurologic deficits in the rat SAH model. Conclusions Given the potential adverse effects of HTS therapies, including hyperchloremic acidosis, and the lack of benefit found in our study, more investigation is required to evaluate the clinical use of 3%HTS in the setting of SAH. © 2008 Springer-Verlag/Wien.
AB - Background Hypertonic saline (HTS) has been proposed as a treatment after aneurysmal subarachnoid hemorrhage (SAH) to minimize ischemic brain injury due to its osmotic and rheologic properties. Although the benefits of 7.2% HTS use in brain injury have been studied, there is a paucity of data on the use of 3%HTS. Methods We investigated whether 3%HTS can reduce brain water content and improve neurologic function after SAH in the rodent model compared to 0.9% saline solution (NS). Neurologic testing was conducted at 24 hours post-SAH prior to sacrificing animals for brain water content evaluation. Findings There was significant potentiation of brain water content in the right hemisphere between 3%HTS and NS groups. The modified Garcia score was not significantly different between the two groups; however, the vibrissae-stimulated forelimb placement test showed significantly lower scores in the HTS group. 3%HTS does not decrease brain edema or improve neurologic deficits as compared to NS. In fact, our study showed 3%HTS potentiated brain edema and worsened neurologic deficits in the rat SAH model. Conclusions Given the potential adverse effects of HTS therapies, including hyperchloremic acidosis, and the lack of benefit found in our study, more investigation is required to evaluate the clinical use of 3%HTS in the setting of SAH. © 2008 Springer-Verlag/Wien.
KW - Brain edema
KW - Hypertonic saline
KW - Intracranial pressure
KW - Subarachnoid hemorrhage
KW - Rats
KW - Male
KW - Brain Edema/drug therapy
KW - Rats, Sprague-Dawley
KW - Saline Solution, Hypertonic/therapeutic use
KW - Subarachnoid Hemorrhage/complications
KW - Animals
KW - Neurologic Examination/methods
KW - Disease Models, Animal
UR - https://link.springer.com/chapter/10.1007%2F978-3-211-85578-2_79
UR - https://www.mendeley.com/catalogue/a012e393-5939-32ce-a67f-d5ea6d0b1fa6/
U2 - 10.1007/978-3-211-85578-2_79
DO - 10.1007/978-3-211-85578-2_79
M3 - Conference contribution
C2 - 19388356
SN - 9783211855775
SN - 978-3-211-99942-4
T3 - Acta Neurochirurgica, Supplementum
SP - 405
EP - 408
BT - Intracranial Pressure and Brain Monitoring XIII
PB - Springer Vienna
ER -